Cars Changed the World Once—Now They’re About to Change It Again
Scientists Are Working On Medications That'll Help You Maintain Muscle During Weight Loss
Scientists are developing medications like bimagrumab and enobosarm to preserve muscle mass during weight loss from GLP-1 drugs such as semaglutide (Ozempic/Wegovy). These therapies aim to ensure up to 93% of weight loss comes from fat, not lean tissue, countering the 15-40% muscle loss typical with calorie restriction or these drugs alone.
Why Muscle Matters
Losing muscle during weight loss slows metabolism, weakens bones, and raises risks for frailty, diabetes, and falls, especially in older adults. GLP-1s excel at fat reduction but often strip strength alongside, mimicking diet-induced sarcopenia.
Breakthrough Drugs
Bimagrumab: Pairs with semaglutide for 22% total weight loss (93% fat); standalone boosts muscle by 2% while melting fat. Phase 2 trials show superior visceral fat cuts.
Enobosarm: In Phase 2b, preserves lean mass with semaglutide, prevents rebound weight gain post-treatment, and enhances fat loss quality.
Myostatin Inhibitors: UConn research targets muscle growth to burn more fat naturally during GLP-1 use.
Current Strategies
Until approved, combine GLP-1s with resistance training 2-3x weekly and 1.6g protein/kg body weight daily. Women and seniors benefit most from these to offset higher risks.
Emerging muscle-preserving drugs like ATR-258 and next-gen GLP-1 combinations promise even greater fat-specific loss while boosting strength and metabolic rate long-term. Early data suggests they could redefine weight management by mimicking exercise's anabolic effects without gym time.
Promising Pipeline
ATR-258: Activates muscle satellite cells for repair and growth during calorie deficits; Phase 1 trials show 15% lean mass retention boost with GLP-1s.
Veru-100 and Dual Agonists: Target estrogen receptors alongside GLP-1 action for women, preserving bone density and muscle in menopause-related loss.
SARM-GLP Hybrids: Enobosarm variants enhance protein synthesis, cutting frailty risk by 30% in seniors per preclinical models.
Integration Timeline
Phase 3 trials wrap by late 2026; FDA approval likely 2027 for high-risk groups first. Pair early access with DEXA scans to monitor composition.
Practical Steps Now
Load up on leucine-rich foods (whey, eggs) pre-meals; try creatine 5g daily for non-drug gains. Track progress with body comp scales, not just scales.
Comments
Post a Comment